November 3, 2015
Over the last two years, big pharma has gotten behind the idea of smartphone-connected inhalers for asthma and COPD in a big way. Two acquisitions, a $3 million investment, and a number of pilot and partnership deals have shown clearly that the space is of interest. (MobiHealthNews is helping to put on two pharma-related events at the mHealth Summit next week -- be sure to join us if you'll be in...
September 30, 2015
Adherium, the Australian connected inhaler company that partnered with AstraZeneca earlier this summer, has released data from three small studies of the company's Smartinhaler system. Data from the studies, all of which involved children and adolescents, indicate a 144 percent increase in adherence for patients using the connected devices, a 14.9 percent increase in lung function and a 37...
August 19, 2015
Adherium Limited, a New Zealand company working on a smart inhaler, has raised $25.6 million ($35 million AU) in an initial public offering on the Australian Securities Exchange, including a $3 million investment from its partner pharma company AstraZeneca, which just last month announced a longterm commercialization agreement with the company.
Adherium makes a line of medical devices that...
July 27, 2015
AstraZeneca has partnered with New Zealand-based Adherium Limited, which offers a mobile-enabled inhaler, to incorporate digital health offerings into AstraZeneca’s patient support programs for people with COPD and asthma.
Adherium's Smartinhaler sends data on when medication was taken to mobile devices and desktop computers via Bluetooth. The platform is designed to help patients, caregivers,...